ADJUVANT XELOX CHEMOTHERAPY OUTCOMES IN HIGH-RISK STAGE II AND STAGE III COLON CANCER: EVIDENCE FROM THAI BINH GENERAL HOSPITAL. YHCĐ 2026, 67 (10). https://doi.org/10.52163/yhc.v67i10.6908.